Clowes Howard 4

What Happened

• Director Clowes Howard was granted two awards of Restricted Stock Units (RSUs) on 2026-05-14 totaling 7,372 RSUs (3,686 + 3,686). Each RSU is a contingent right to one share of Plus Therapeutics common stock; the awards show a $0 acquisition price (derivative awards), not an open‑market purchase or sale. This is an equity compensation grant rather than a cash transaction.

Key Details

• Transaction date: May 14, 2026; Form 4 filed May 18, 2026 (timely — within two business days).
• Type/code: A = Award/Grant (derivative RSUs), reported at $0.00 per RSU.
• Quantity: 7,372 RSUs total (3,686 + 3,686).
• Shares owned after transaction: Not specified in the provided filing.
• Notable footnotes:
  • F1: Each RSU converts to one share when vested; the RSUs vest ratably over four quarters in equal 1/4 increments, with the first 1/4 vesting on July 1, 2026 and the remainder quarterly thereafter.
  • F2: Describes an options vesting schedule (monthly over 12 months, with full vesting at the 2027 Annual Meeting) — this applies to options referenced in the filing footnotes but no option exercise/sale was reported in the transactions above.

Context

• RSU grants are a form of compensation and become actual shares only as they vest; they are not an immediate purchase signal. Because these awards vest over time, their conversion to tradable shares depends on continued service/vesting conditions noted in F1 (and F2 for any option grants). No sale or purchase of shares occurred in this filing.